NDC 72603-105 Fulvestrant
View Dosage, Usage, Ingredients, Routes, UNII
Product Information
Get all the details for National Drug Code (NDC) 72603-105 in one place. This page breaks down everything you need to know about the NDC, including proprietary name, active and inactive substances, package configurations, billing units, labeler information, and routes of administration. It also includes enhanced data such as HCPCS codes, FDA product labels with images, UNIIs, and RxNorm cross-references. Whether you're a healthcare professional verifying drug data or a consumer researching medication, this NDC page helps you make informed, accurate decisions.
Code Structure Chart
Product Details
What is NDC 72603-105?
What are the uses for Fulvestrant?
Which are Fulvestrant UNII Codes?
The UNII codes for the active ingredients in this product are:
- FULVESTRANT (UNII: 22X328QOC4)
- FULVESTRANT (UNII: 22X328QOC4) (Active Moiety)
Which are Fulvestrant Inactive Ingredients UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- ALCOHOL (UNII: 3K9958V90M)
- BENZYL ALCOHOL (UNII: LKG8494WBH)
- BENZYL BENZOATE (UNII: N863NB338G)
- CASTOR OIL (UNII: D5340Y2I9G)
* Please review the disclaimer below.
Patient Education
Fulvestrant Injection
Fulvestrant injection is used alone or in combination with ribociclib (Kisqali®) to treat a certain type of hormone receptor positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer has spread to other parts of the body in women who have experienced menopause (change of life; end of monthly menstrual periods) and have not previously been treated with an anti-estrogen medication such as tamoxifen (Nolvadex). Fulvestrant injection is also used alone or in combination with ribociclib (Kisqali®) to treat hormone receptor positive, advanced breast cancer or breast cancer that has spread to other parts of the body in women who have experienced menopause and whose breast cancer has worsened after they were treated with an anti-estrogen medication such as tamoxifen. Fulvestrant injection is also used in combination with palbociclib (Ibrance®) or abemaciclib (Verzenio®) to treat hormone receptor positive, advanced breast cancer in women whose breast cancer has spread to other parts of the body and has worsened after they were treated with anti-estrogen medication such as tamoxifen. Fulvestrant is in a class of medications called estrogen receptor antagonists. It works by blocking the action of estrogen on cancer cells. This can slow or stop the growth of some breast tumors that need estrogen to grow.
[Learn More]
Cancer Chemotherapy
What is cancer chemotherapy?
Cancer chemotherapy is a type of cancer treatment. It uses medicines to destroy cancer cells.
Normally, the cells in your body grow and die in a controlled way. Cancer cells keep growing without control. Chemotherapy works by killing the cancer cells, stopping them from spreading, or slowing their growth.
Chemotherapy is used to:
- Treat cancer by curing the cancer, lessening the chance it will return, or stopping or slowing its growth.
- Ease cancer symptoms by shrinking tumors that are causing pain and other problems.
What are the side effects of chemotherapy?
Chemotherapy does not just destroy cancer cells. It can also harm some healthy cells, which causes side effects.
You may have a lot of side effects, some side effects, or none at all. It depends on the type and amount of chemotherapy you get and how your body reacts.
Some common side effects are:
- Mouth sores
- Fatigue
- Nausea and vomiting
- Pain
- Hair loss
There are ways to prevent or control some side effects. Talk with your health care provider about how to manage them. Healthy cells usually recover after chemotherapy is over, so most side effects gradually go away.
What can I expect when getting chemotherapy?
You may get chemotherapy in a hospital or at home, a doctor's office, or a medical clinic. You might be given the medicines by mouth, in a shot, as a cream, through a catheter, or intravenously (by IV).
Your treatment plan will depend on the type of cancer you have, which chemotherapy medicines are used, the treatment goals, and how your body responds to the medicines.
Chemotherapy may be given alone or with other treatments. You may get treatment every day, every week, or every month. You may have breaks between treatments so that your body has a chance to build new healthy cells.
NIH: National Cancer Institute
[Learn More]
* Please review the disclaimer below.
[5] What is the Labeler Name? - Name of Company corresponding to the labeler code segment of the Product NDC.
[6] What is the FDA Application Number? - This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
[8] What is the Marketing Category? - Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
[9] What is the Start Marketing Date? - This is the date that the labeler indicates was the start of its marketing of the drug product.
[10] What is the End Marketing Date? - This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
[11] What is the Listing Expiration Date? - This is the date when the listing record will expire if not updated or certified by the product labeler.
[12] What is the NDC Exclude Flag? - This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions, or because the listing certification is expired, or because the listing data was inactivated by FDA, or because it was discontinued by the labeler. Possible values in this field are: "D", "E", "I", "N", "U".